Biocon Ltd (BIOCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Biocon Ltd (BIOCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH27810D
  • |
  • Pages: 87
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions like cancer, diabetes and autoimmune. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations; and complex biologics both novels and biosimilars including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs. It also provides research services including discovery, development and manufacturing services for both small and large molecules. Biocon provides research solutions to the biotechnology and pharmaceutical companies worldwide. It has an overseas manufacturing facility at BioXcell, a biotechnology park in Johor, Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.

Biocon Ltd (BIOCON)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Biocon Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Biocon Biologics India to Acquire Biosimilars Business from Biocon 14

Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences 15

Venture Financing 16

Syngene May Raise Over USD50 Million in Venture Financing 16

Private Equity 17

Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 17

IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 19

GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For USD 23 Million 20

Partnerships 22

Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 22

Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 23

Syngene International Enters into Agreement with Zumutor Biologics 24

Sandoz International Enters into Agreement with Biocon 25

Biocon Enters into Agreement with Juvenile Diabetes Research Foundation 26

Biocon Enters into Co-Development Agreement with Laboratorios PiSA 27

Saniona Enters into Agreement with Syngene 28

Syngene International Extends R&D Agreement with Bristol-Myers Squibb 29

CytoSorbents Expands Co-Marketing Agreement with Biocon 30

Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab 31

Biocon Plans To Enter Into Co-Development Agreement For Biosimilars 32

Abbott India Enters Into Joint Venture Agreement With Syngene International 33

Licensing Agreements 34

Equillium Enters into Licensing Agreement with Biocon 34

Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 36

Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products 38

Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 39

Biocon Enters into Licensing Agreement with Gilead Sciences 40

Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 41

Equity Offering 42

Biocon May Raise up to USD500 Million in Public Offering 42

Syngene International Raises up to USD86 Million in IPO 43

Asset Transactions 45

Biocon Biologics India to Acquire Biosimilars Business from Biocon 45

Biocon Ltd-Key Competitors 46

Biocon Ltd-Key Employees 47

Biocon Ltd-Locations And Subsidiaries 48

Head Office 48

Other Locations & Subsidiaries 48

Joint Venture 48

Recent Developments 50

Strategy And Business Planning 50

Aug 11, 2017: Biocon Announces Incorporation of a Wholly Owned Subsidiary in Malaysia 50

Financial Announcements 51

Oct 25, 2018: Biocon announces financial results for the second quarter ended on September 30th, 2018 51

Jul 26, 2018: Biocon Q1FY19 revenue Rs 1,193 Cr, Up 21%; EBITDA up 25% at Rs 307 Cr; net profit up 47% at Rs 120 Cr 54

Apr 26, 2018: Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr[TOPC : Pharma-Biocon Ltd] 57

Oct 26, 2017: Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore 60

Jul 27, 2017: Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore 63

Apr 27, 2017: Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr 67

Jan 24, 2017: Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore 70

Legal and Regulatory 73

Sep 22, 2018: Biocon's drug substance facility in bangalore completes US FDA inspection with No observations 73

Jul 04, 2018: Biocon's Sterile Drug Product facility Receives EU GMP Certification 74

Jun 23, 2018: Biocon's Sterile Drug Product facility Receives EIR from U.S. FDA 75

May 02, 2018: Biocon Regulatory Audit Update 76

Mar 13, 2018: Update On Company Statement On US-FDA Inspection At Biocon Malaysia 77

Feb 21, 2018: Biocon Announces US-FDA Inspection at Malaysian Manufacturing Facility 78

Nov 20, 2017: Biocon's Drug product Facility Receives EIR with VAI status, Inspection Closed 79

Sep 18, 2017: Biocon's Facility in Vishakhapatnam completes USFDA Inspection with no observations 80

Jul 09, 2017: Biocon provides update on Bangalore Facility 81

Jul 09, 2017: Biocon: Update on Inspection Audits by French health agency 82

May 10, 2017: Biocon statement in response to media reports on USFDA Form 483s for Biocon Limited 83

Other Significant Developments 84

Dec 13, 2017: Biocon's Clarification post media reports on Biocon on the FDA list for not paying facility fee 84

Oct 06, 2017: Biocon: No Separate Audit or Observations by Health Canada 85

May 05, 2017: Biocon: Company Statement Media Reports on USFDA 483s 86

Appendix 87

Methodology 87

About GlobalData 87

Contact Us 87

Disclaimer 87

List of Figures

Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11

List of Tables

Biocon Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Biocon Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Biocon Biologics India to Acquire Biosimilars Business from Biocon 14

Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences 15

Syngene May Raise Over USD50 Million in Venture Financing 16

Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 17

IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 19

GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For USD 23 Million 20

Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 22

Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 23

Syngene International Enters into Agreement with Zumutor Biologics 24

Sandoz International Enters into Agreement with Biocon 25

Biocon Enters into Agreement with Juvenile Diabetes Research Foundation 26

Biocon Enters into Co-Development Agreement with Laboratorios PiSA 27

Saniona Enters into Agreement with Syngene 28

Syngene International Extends R&D Agreement with Bristol-Myers Squibb 29

CytoSorbents Expands Co-Marketing Agreement with Biocon 30

Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab 31

Biocon Plans To Enter Into Co-Development Agreement For Biosimilars 32

Abbott India Enters Into Joint Venture Agreement With Syngene International 33

Equillium Enters into Licensing Agreement with Biocon 34

Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 36

Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products 38

Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 39

Biocon Enters into Licensing Agreement with Gilead Sciences 40

Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 41

Biocon May Raise up to USD500 Million in Public Offering 42

Syngene International Raises up to USD86 Million in IPO 43

Biocon Biologics India to Acquire Biosimilars Business from Biocon 45

Biocon Ltd, Key Competitors 46

Biocon Ltd, Key Employees 47

Biocon Ltd, Subsidiaries 48

Biocon Ltd, Joint Venture 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Biocon Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com